References

S
Sise ME, Goldberg DS, Kort JJ, et al. Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol. 2020;31(11):2678-2687.
Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157(11):817-822.
Smith DA, Bradshaw D, Mbisa JL, et al. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. J Viral Hepat. 2021;28(9):1256-1264. doi:10.1111/jvh.13549.
Smith DE, Chen S, Fargnoli A, et al. Impact of early initiation of direct-acting antiviral therapy in thoracic organ transplantation from hepatitis C virus positive donors. Semin Thorac Cardiovasc Surg. 2021;33(2):407-415.
Smith BD, Morgan RL, Beckett GA, et al, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. Falck-Ytter Y, Holtzman D, Teo CG, et al., eds. MMWR Recomm Rep. 2012;61(RR-4):1-32.
Smith BD, Jewett A, Burt RD, Zibbell JE, Yartel AK, DiNenno E. "To share or not to share?" Serosorting by hepatitis C status in the sharing of drug injection equipment among NHBS-IDU2 participants. J Infect Dis. 2013;208(12):1934-1942.
Smolders EJ, Colbers EP, de Kanter CT, et al. Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat. Velthoven-Graafland K, Drenth JPH, Burger DM, eds. J Antimicrob Chemother. 2017;72(2):486-489.
Smookler D, Vanderhoff A, Biondi MJ, et al. Reducing read time of point-of-care test does not affect detection of hepatitis C virus and reduces need for reflex RNA. Clin Gastroenterol Hepatol. 2020;S1542-3565(20):31068-5.
Sobotka LA, Mumtaz K, Wellner MR, et al. Outcomes of Hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: a large single center analysis. Ann Hepatol. 2021;24. doi:10.1016/j.aohep.2021.100318.
Söderholm J, Millbourn C, Büsch K, et al. Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. J Hepatol. 2018;68(5):904-911. doi:10.1016/j.jhep.2017.12.003.
Solomon SS, Wagner-Cardoso S, Smeaton L, Smeaton L. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022;7(4):307-317. doi:10.1016/S2468-1253(21)00397-6.
Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;(357):j1550.
Soriano V, Barreiro P, deMendoza C. Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology. 2016;(63):2065-2066.
Soriano V, Benítez-Gutiérrez L, Arias A, et al. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opin Drug Metab Toxicol. 2017;13(9):1015-1022.
Spaulding AS, Kim AY, Harzke AJo, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Sullivan JC, Linas BP, Brewer A, et al., eds. Top Antivir Med. 2013;21(1):27-35.
Spaulding AC, Weinbaum CM, Lau DT, et al. A framework for management of hepatitis C in prisons. Sterling RK, Seeff LB, Margolis HS, Hoofnagle JH, eds. Ann Intern Med. 2006;144(10):762-769.
Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA. 2012;307(12):1259-1260.
Spaulding AC, Sharma A, Messina LC, et al. A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. Zlotorzynska M, Miller L, Binswanger IA, eds. Am J Public Health. 2015;105(5):e51-e57.
Spaulding AC, Seals RM, McCallum VA, Perez SD, Brzozowski AK, Steenland NK. Prisoner survival inside and outside of the institution: implications for health-care planning. Am J Epidemiol. 2011;173(5):479-487.
Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat. 2012;43(4):424-432.
Top